Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Benjamin D. Noll
Observed names:
B. Noll,
Benjamin D Noll,
Benjamin Noll
Institution:
University of South Australia
Observed institutions:
Royal Adelaide Hospital,
University of South Australia,
Erasmus MC,
Basil Hetzel Institute,
Queen Elizabeth Hospital,
Centre for Cancer Biology,
The University of Adelaide
show all 7
ORCID:
0000-0001-7673-8341
Observed ORCID:
0000-0001-7673-8341
OpenAlex ID:
A5076737013
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol- N -(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
2017
·
Solomon Tadesse
, Mingfeng Yu
, et al.
·
Journal of Medicinal Chemistry
·
82
Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods
2010
·
Benedetta C. Sallustio
, Benjamin D. Noll
, et al.
·
Clinical Biochemistry
·
82
Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists
2017
·
James O'Brien-Brown
, Alexander Jackson
, et al.
·
European Journal of Medicinal Chemistry
·
39
Validation of an LC–MS/MS Method to Measure Tacrolimus in Rat Kidney and Liver Tissue and Its Application to Human Kidney Biopsies
2013
·
Benjamin D. Noll
, Janet K. Coller
, et al.
·
Therapeutic Drug Monitoring
·
38
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents
2017
·
Solomon Tadesse
, Laychiluh Bantie
, et al.
·
British Journal of Pharmacology
·
29
PDF
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients
2021
·
Benedetta C. Sallustio
, Benjamin D. Noll
, et al.
·
British Journal of Clinical Pharmacology
·
27
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer
2020
·
Laychiluh Bantie
, Solomon Tadesse
, et al.
·
Gynecologic Oncology
·
25
Validation of an LC–MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies
2013
·
Zaipul I. Md Dom
, Benjamin D. Noll
, et al.
·
Journal of Chromatography B
·
24
Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation
2021
·
Mingfeng Yu
, Theodosia Teo
, et al.
·
European Journal of Medicinal Chemistry
·
22
Measurement of Cyclosporine A in Rat Tissues and Human Kidney Transplant Biopsies—A Method Suitable for Small (<1 mg) Samples
2011
·
Benjamin D Noll
, Janet K Coller
, et al.
·
Therapeutic Drug Monitoring
·
18
An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
2022
·
Abel Tesfaye Anshabo
, Laychiluh Bantie
, et al.
·
Cancers
·
17
PDF
Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
2021
·
Mingfeng Yu
, Yi Long
, et al.
·
European Journal of Medicinal Chemistry
·
14
Sulfonamide-Based Inhibitors of Biotin Protein Ligase as New Antibiotic Leads
2019
·
Kwang Jun Lee
, William Tieu
, et al.
·
ACS Chemical Biology
·
13
A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner
2016
·
Selina K. Sutton
, Daniel R. Carter
, et al.
·
Oncotarget
·
11
PDF
A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma
2025
·
Laychiluh B. Mekonnen
, Theodosia Teo
, et al.
·
Biomedicine & Pharmacotherapy
·
8
Relationship between allograft cyclosporin concentrations and P‐glycoprotein expression in the 1st month following renal transplantation
2019
·
Benedetta C. Sallustio
, Benjamin D. Noll
, et al.
·
British Journal of Clinical Pharmacology
·
8
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
2023
·
Saiful Islam
, Muhammed H. Rahaman
, et al.
·
Cancers
·
6
PDF
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity
2018
·
Ahmed M. Abdelaziz
, Sarah Diab
, et al.
·
Medicinal Chemistry
·
6
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma
2026
·
T. Teo
, J. Karanjia
, et al.
·
ESMO Open
·
2
Abstract 5701: AU2-94: A CDK4-specific inhibitor with the marked anti-tumor efficacy
2024
·
Laychiluh Bantie
, Jimma Likisa
, et al.
·
Cancer Research
·
2
Erratum to “A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer” [Gynecologic Oncology 159 (2020) 827–838]
2021
·
Laychiluh Bantie
, Solomon Tadesse
, et al.
·
Gynecologic Oncology
PDF
Preclinical development of CDDD3-14, a potent and selective inhibitor of CDK4/6 for the treatment of breast cancer
2019
·
Laychiluh Bantie
, Solomon Tadesse
, et al.
·
Oncology Abstracts
Abstract 1524: A first-in-class CDK4 inhibitor shows excellent in vitro and in vivo efficacy against ovarian cancer
2018
·
Laychiluh B. Mekonnen
, Solomon Zeleke
, et al.
·
Cancer Research
Abstract 2314: Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancer
2018
·
Laychiluh Bantie
, Solomon Tadesse
, et al.
·
Cancer Research
Abstract 2353: CDKI-15, a novel and highly selective CDK4/6 inhibitor: discovery, in vitro and in vivo anticancer efficacy
2017
·
Solomon Tadesse
, Laychiluh Bantie
, et al.
·
Cancer Research
Show more works
View as search
Works count:
25
Citation count:
473
H-index:
13
I10-index:
14
Year
Topic
Type